biolitec AG, headquartered in Austria, is a pioneering company in the field of medical technology, specialising in innovative laser therapies. Founded in 1988, biolitec has established itself as a leader in minimally invasive treatment solutions, particularly in the areas of urology, gynaecology, and oncology. The company is renowned for its unique laser systems, which utilise advanced technologies to enhance surgical precision and patient outcomes. With a strong presence in Europe and expanding operations globally, biolitec AG has achieved significant milestones, including numerous patents and regulatory approvals for its cutting-edge products. Recognised for its commitment to quality and innovation, biolitec AG continues to set benchmarks in the medical device industry, making it a trusted partner for healthcare professionals worldwide.
How does biolitec AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
biolitec AG's score of 14 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
biolitec AG, headquartered in Austria (AT), currently does not report specific carbon emissions data, as no figures are available. The company is a current subsidiary and does not inherit emissions data from a parent organization. Consequently, there are no documented reduction targets or climate pledges at this time. In the context of the industry, biolitec AG may be expected to align with common climate commitments, such as those outlined by the Science Based Targets initiative (SBTi) or similar frameworks, although no specific initiatives or targets have been disclosed. As a participant in the healthcare and technology sectors, biolitec AG is likely aware of the growing emphasis on sustainability and carbon footprint reduction, which may influence future commitments and reporting practices.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
biolitec AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
